To assess the cascade of care for opioid use disorder (OUD) among Medicaid beneficiaries from July 2018 to December 2023.
Key Findings:
In 2022, 71% of Medicaid beneficiaries diagnosed with OUD received MOUD.
56% to 58% of beneficiaries receiving MOUD continued treatment for at least 180 days.
Medicaid prescriptions for MOUD increased from 14.9 to 19.1 per 1000 population from 2018 to 2023.
Interpretation:
The study highlights improvements in access to and continuity of MOUD among Medicaid beneficiaries, indicating progress in addressing OUD treatment.
Limitations:
Exclusion of certain states due to data limitations, which may affect the generalizability of the findings.
Potential inaccuracies in claims data affecting the assessment of MOUD continuity.
Conclusion:
The findings suggest a positive trend in the treatment of OUD among Medicaid recipients, emphasizing the importance of sustained treatment to reduce overdose deaths, supported by specific data points.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
